ACTL9

Across TCGA pan-cancer cohorts, ACTL9 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACTL9 data layer compared with 11 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher ACTL9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACTL9 expression acts as an unfavorable survival marker.

LGG, LUAD, and UCS are the cancer types where ACTL9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	DFS	Median	All	0.058	0.834	<.001	18	view →
LUAD	OS	Median	II,III,IV	0.111	0.750	<.001	12	view →
UCS	DFS	Median	All	0.136	0.523	.034	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACTL9–LGG (DFS)

Open the LGG breakdown →